感染症ワクチン市場：製品別、感染症別、エンドユーザー別-2025～2030年の世界予測

感染症ワクチン市場は、2023年に300億1,000万米ドルと評価され、2024年には318億3,000万米ドルに達すると予測され、CAGR 8.98％で成長し、2030年には548億3,000万米ドルに達すると予測されています。

感染症ワクチンは、身体の免疫反応を刺激することで、様々な感染症に対する免疫を提供する生物製剤です。感染症ワクチンの必要性は、疾病の発生を予防し、罹患率と死亡率を減少させ、群衆免疫を達成する上で重要な役割を果たすため、最も重要です。これらのワクチンの用途は、インフルエンザ、肝炎、麻疹、COVID-19などの疾病を対象とした公衆衛生プログラム、個別予防接種、世界ヘルスイニシアチブに及んでいます。最終用途には、政府の医療部門、病院、クリニック、研究機関などが含まれ、これらすべてが集団予防接種キャンペーンや個別予防医療にワクチンを利用しています。感染症ワクチン市場に影響を与える主要成長要因としては、予防医療に対する意識の高まり、ワクチン開発における技術的発展、予防接種に対する政府の取り組み、ワクチン研究への旺盛な資金提供などが挙げられます。新興国市場開拓の原動力となっているのは、パンデミック時や急速に変異するウイルスに対する可能性を秘めたmRNAベースワクチンや多価ワクチンなどの新規ワクチンの開発です。企業は、研究への投資や、ワクチンの流通網を拡大するための政府・非政府組織との提携を確保することで、こうした機会を活用することができます。しかし、研究開発コストの高さ、規制の枠組みの厳しさ、ワクチンの接種をためらう人々など、市場の成長を阻害しかねない制限や課題に直面しています。成長のための革新的なセグメントとしては、個別化ワクチン、コールドチェーンの課題を軽減する耐熱性ワクチン、使いやすさを向上させる無針送達システムなどがあります。市場洞察はまた、ワクチンの流通とモニタリングのためのデジタルプラットフォームへのシフトを示しており、これによりサプライチェーンと接種後のフォローアップを最適化することができます。市場力学はダイナミックで競争が激しく、継続的なイノベーションと公衆衛生環境の変化や新興疾患への適応が必要です。

市場力学：急速に進化する感染症ワクチン市場の主要市場洞察を公開

感染症ワクチン市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネス機会の獲得を行うことができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • HIV、がん、糖尿病を含む慢性疾患の高い蔓延
  • 流行性疾患の抑制に向けた政府の重点的な活動
  • 健康に関する消費者の意識と支出の増加
• 市場抑制要因
  • ワクチン製造に必要な高コストと長期化するスケジュール
• 市場機会
  • 官民による研究開発投資の増加
  • 新しい感染症ワクチンの採用
• 市場課題
  • ワクチンの副作用や有害事象の可能性

ポーターのファイブフォース：感染症ワクチン市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォースフレームワークは、企業の競合を評価し、戦略的機会を探るための明確な手法を記載しています。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これら洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：感染症ワクチン市場における外部からの影響の把握

外部マクロ環境要因は、感染症ワクチン市場の業績力学を形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を記載しています。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析：感染症ワクチン市場における競合情勢の把握

感染症ワクチン市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、セグメント化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的な意思決定を行うために必要な知見を得ることができます。

FPNVポジショニングマトリックス：感染症ワクチン市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、感染症ワクチン市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によりベンダーを明確かつ的確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨：感染症ワクチン市場における成功への道筋を描く

感染症ワクチン市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネス機会を活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目セグメントを網羅した市場の包括的な分析を提供しています。

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力を評価します。

2.市場の開拓度：新興市場における成長機会を特定し、既存セグメントにおける拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを記載しています。

3.市場の多様化：最近の製品発売、未開拓の地域、産業の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発とイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています。

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、地域はどこか？

3.市場を形成する主要技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • HIV、がん、糖尿病などの慢性疾患の有病率が高い
    • 伝染病の抑制に向けた政府の重点的な活動
    • 健康に関する消費者の意識と支出の増加
  • 抑制要因
    • ワクチン製造には高いコストと長い期間が必要
  • 機会
    • 研究開発への公的と民間セクターによる投資の増加
    • 新規感染症ワクチンの採用
  • 課題
    • ワクチンの副作用や有害事象の可能性
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治
  • 経済
  • 社会
  • 技術
  • 法律
  • 環境

第6章 感染症ワクチン市場：製品別

• イントロダクション
• 予防ワクチン
• 治療ワクチン

第7章 感染症ワクチン市場：感染症別

• イントロダクション
• アレルギー
• 子宮頸がん
• DTP
• 肝炎
• インフルエンザ
• 髄膜炎菌
• MMR
• 肺炎球菌
• ポリオ
• ロタウイルス
• 水痘

第8章 感染症ワクチン市場：エンドユーザー別

• イントロダクション
• 成人
• 小児

第9章 南北アメリカの感染症ワクチン市場

• イントロダクション
• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋の感染症ワクチン市場

• イントロダクション
• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの感染症ワクチン市場

• イントロダクション
• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析、2023年
• FPNVポジショニングマトリックス、2023年
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Abbott Laboratories
• Astellas Pharma, Inc.
• AstraZeneca PLC
• Bavarian Nordic A/S
• Bharat BIoTech
• Biological E Ltd.
• CSL Limited
• DAIICHI SANKYO COMPANY, LIMITED
• Emergent BioSolutions Inc.
• GlaxoSmithKline PLC
• Incepta Vaccine, Ltd.
• Johnson and Johnson Services Inc.
• Lonza Group AG
• Merck & Co., Inc.
• Mitsubishi Tanabe Pharma Corporation
• Novartis International AG
• Novavax, Inc.
• Pfizer, Inc.
• Sanofi SA
• Serum Institute of India Pvt., Ltd
• Sinovac BIoTech Ltd.

LIST OF FIGURES

• FIGURE 1. INFECTIOUS VACCINES MARKET RESEARCH PROCESS
• FIGURE 2. INFECTIOUS VACCINES MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL INFECTIOUS VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS INFECTIOUS VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS INFECTIOUS VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES INFECTIOUS VACCINES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES INFECTIOUS VACCINES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC INFECTIOUS VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC INFECTIOUS VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. INFECTIOUS VACCINES MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. INFECTIOUS VACCINES MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. INFECTIOUS VACCINES MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL INFECTIOUS VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. INFECTIOUS VACCINES MARKET DYNAMICS
• TABLE 7. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PREVENTIVE VACCINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY THERAPEUTIC VACCINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY ALLERGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY CERVICAL CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY DTP, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY HEPATITIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INFLUENZA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY MENINGOCOCCAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY MMR, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PNEUMOCOCCAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY POLIO, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY ROTAVIRUS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY VARICELLA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY ADULTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PEDIATRICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. AMERICAS INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 26. AMERICAS INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
• TABLE 27. AMERICAS INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 28. AMERICAS INFECTIOUS VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 29. ARGENTINA INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 30. ARGENTINA INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
• TABLE 31. ARGENTINA INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 32. BRAZIL INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 33. BRAZIL INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
• TABLE 34. BRAZIL INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 35. CANADA INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 36. CANADA INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
• TABLE 37. CANADA INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 38. MEXICO INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 39. MEXICO INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
• TABLE 40. MEXICO INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 41. UNITED STATES INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 42. UNITED STATES INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
• TABLE 43. UNITED STATES INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 44. UNITED STATES INFECTIOUS VACCINES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 45. ASIA-PACIFIC INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 46. ASIA-PACIFIC INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
• TABLE 47. ASIA-PACIFIC INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 48. ASIA-PACIFIC INFECTIOUS VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 49. AUSTRALIA INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 50. AUSTRALIA INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
• TABLE 51. AUSTRALIA INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 52. CHINA INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 53. CHINA INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
• TABLE 54. CHINA INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 55. INDIA INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 56. INDIA INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
• TABLE 57. INDIA INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 58. INDONESIA INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 59. INDONESIA INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
• TABLE 60. INDONESIA INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 61. JAPAN INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 62. JAPAN INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
• TABLE 63. JAPAN INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 64. MALAYSIA INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 65. MALAYSIA INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
• TABLE 66. MALAYSIA INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 67. PHILIPPINES INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 68. PHILIPPINES INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
• TABLE 69. PHILIPPINES INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 70. SINGAPORE INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 71. SINGAPORE INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
• TABLE 72. SINGAPORE INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 73. SOUTH KOREA INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 74. SOUTH KOREA INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
• TABLE 75. SOUTH KOREA INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 76. TAIWAN INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 77. TAIWAN INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
• TABLE 78. TAIWAN INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 79. THAILAND INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 80. THAILAND INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
• TABLE 81. THAILAND INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 82. VIETNAM INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 83. VIETNAM INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
• TABLE 84. VIETNAM INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 85. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 86. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
• TABLE 87. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 88. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 89. DENMARK INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 90. DENMARK INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
• TABLE 91. DENMARK INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 92. EGYPT INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 93. EGYPT INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
• TABLE 94. EGYPT INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 95. FINLAND INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 96. FINLAND INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
• TABLE 97. FINLAND INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 98. FRANCE INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 99. FRANCE INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
• TABLE 100. FRANCE INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 101. GERMANY INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 102. GERMANY INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
• TABLE 103. GERMANY INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 104. ISRAEL INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 105. ISRAEL INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
• TABLE 106. ISRAEL INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 107. ITALY INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 108. ITALY INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
• TABLE 109. ITALY INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 110. NETHERLANDS INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 111. NETHERLANDS INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
• TABLE 112. NETHERLANDS INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 113. NIGERIA INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 114. NIGERIA INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
• TABLE 115. NIGERIA INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 116. NORWAY INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 117. NORWAY INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
• TABLE 118. NORWAY INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 119. POLAND INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 120. POLAND INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
• TABLE 121. POLAND INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 122. QATAR INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 123. QATAR INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
• TABLE 124. QATAR INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 125. RUSSIA INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 126. RUSSIA INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
• TABLE 127. RUSSIA INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 128. SAUDI ARABIA INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 129. SAUDI ARABIA INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
• TABLE 130. SAUDI ARABIA INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 131. SOUTH AFRICA INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 132. SOUTH AFRICA INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
• TABLE 133. SOUTH AFRICA INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 134. SPAIN INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 135. SPAIN INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
• TABLE 136. SPAIN INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 137. SWEDEN INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 138. SWEDEN INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
• TABLE 139. SWEDEN INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 140. SWITZERLAND INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 141. SWITZERLAND INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
• TABLE 142. SWITZERLAND INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 143. TURKEY INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 144. TURKEY INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
• TABLE 145. TURKEY INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 146. UNITED ARAB EMIRATES INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 147. UNITED ARAB EMIRATES INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
• TABLE 148. UNITED ARAB EMIRATES INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 149. UNITED KINGDOM INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 150. UNITED KINGDOM INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
• TABLE 151. UNITED KINGDOM INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 152. INFECTIOUS VACCINES MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 153. INFECTIOUS VACCINES MARKET, FPNV POSITIONING MATRIX, 2023

The Infectious Vaccines Market was valued at USD 30.01 billion in 2023, expected to reach USD 31.83 billion in 2024, and is projected to grow at a CAGR of 8.98%, to USD 54.83 billion by 2030.

Infectious vaccines are biological preparations that provide immunity against various infectious diseases by stimulating the body's immune response. The necessity for infectious vaccines is paramount due to their critical role in preventing disease outbreaks, reducing morbidity and mortality, and achieving herd immunity. The application of these vaccines spans public health programs, individual immunizations, and global health initiatives targeting diseases such as influenza, hepatitis, measles, and COVID-19. The end-use scope includes government healthcare departments, hospitals, clinics, and research institutions, all of which utilize vaccines for mass immunization campaigns and individual preventive care. Key growth factors influencing the infectious vaccines market include increasing awareness of preventive healthcare, technological advancements in vaccine development, government initiatives for immunization, and the robust funding for vaccine research. Emerging opportunities in the market are driven by the development of novel vaccines, such as mRNA-based vaccines and multi-valent vaccines, which offer potential during pandemics or against rapidly mutating viruses. Companies can capitalize on these opportunities by investing in research and securing partnerships with governmental and non-governmental organizations to expand vaccine distribution networks. However, the market faces limitations and challenges such as high R&D costs, stringent regulatory frameworks, and vaccine hesitancy among populations, which can inhibit market growth. Innovative areas for growth include personalized vaccines, thermostable vaccines that mitigate cold chain challenges, and needle-free delivery systems that enhance ease of use. Market insights also indicate a shift towards digital platforms for vaccine distribution and monitoring, which can optimize supply chains and post-vaccination follow-ups. The nature of the infectious vaccines market is dynamic and highly competitive, necessitating continuous innovation and adaptation to changing public health environments and emerging diseases.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Infectious Vaccines Market

The Infectious Vaccines Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • High prevalence of chronic diseases including HIV, cancer, diabetes
  • Government focused activities to control epidemic diseases
  • Rising consumer awareness and expenditure regarding health
• Market Restraints
  • High costs and longer timelines required for vaccine production
• Market Opportunities
  • Growing investment by public & private sector for R&D endeavors
  • Introduction of novel infectious vaccines
• Market Challenges
  • Possibilities of vaccine side effects and adverse events

Porter's Five Forces: A Strategic Tool for Navigating the Infectious Vaccines Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Infectious Vaccines Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Infectious Vaccines Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Infectious Vaccines Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Infectious Vaccines Market

A detailed market share analysis in the Infectious Vaccines Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Infectious Vaccines Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Infectious Vaccines Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Infectious Vaccines Market

A strategic analysis of the Infectious Vaccines Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Infectious Vaccines Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Astellas Pharma, Inc., AstraZeneca PLC, Bavarian Nordic A/S, Bharat Biotech, Biological E Ltd., CSL Limited, DAIICHI SANKYO COMPANY, LIMITED, Emergent BioSolutions Inc., GlaxoSmithKline PLC, Incepta Vaccine, Ltd., Johnson and Johnson Services Inc., Lonza Group AG, Merck & Co., Inc., Mitsubishi Tanabe Pharma Corporation, Novartis International AG, Novavax, Inc., Pfizer, Inc., Sanofi SA, Serum Institute of India Pvt., Ltd, and Sinovac Biotech Ltd..

Market Segmentation & Coverage

This research report categorizes the Infectious Vaccines Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Product, market is studied across Preventive Vaccine and Therapeutic Vaccine.
• Based on Infectious Disease, market is studied across Allergy, Cervical Cancer, DTP, Hepatitis, Influenza, Meningococcal, MMR, Pneumococcal, Polio, Rotavirus, and Varicella.
• Based on End User, market is studied across Adults and Pediatrics.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. High prevalence of chronic diseases including HIV, cancer, diabetes
    • 5.1.1.2. Government focused activities to control epidemic diseases
    • 5.1.1.3. Rising consumer awareness and expenditure regarding health
  • 5.1.2. Restraints
    • 5.1.2.1. High costs and longer timelines required for vaccine production
  • 5.1.3. Opportunities
    • 5.1.3.1. Growing investment by public & private sector for R&D endeavors
    • 5.1.3.2. Introduction of novel infectious vaccines
  • 5.1.4. Challenges
    • 5.1.4.1. Possibilities of vaccine side effects and adverse events
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Infectious Vaccines Market, by Product

• 6.1. Introduction
• 6.2. Preventive Vaccine
• 6.3. Therapeutic Vaccine

7. Infectious Vaccines Market, by Infectious Disease

• 7.1. Introduction
• 7.2. Allergy
• 7.3. Cervical Cancer
• 7.4. DTP
• 7.5. Hepatitis
• 7.6. Influenza
• 7.7. Meningococcal
• 7.8. MMR
• 7.9. Pneumococcal
• 7.10. Polio
• 7.11. Rotavirus
• 7.12. Varicella

8. Infectious Vaccines Market, by End User

• 8.1. Introduction
• 8.2. Adults
• 8.3. Pediatrics

9. Americas Infectious Vaccines Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Infectious Vaccines Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Infectious Vaccines Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Laboratories
• 2. Astellas Pharma, Inc.
• 3. AstraZeneca PLC
• 4. Bavarian Nordic A/S
• 5. Bharat Biotech
• 6. Biological E Ltd.
• 7. CSL Limited
• 8. DAIICHI SANKYO COMPANY, LIMITED
• 9. Emergent BioSolutions Inc.
• 10. GlaxoSmithKline PLC
• 11. Incepta Vaccine, Ltd.
• 12. Johnson and Johnson Services Inc.
• 13. Lonza Group AG
• 14. Merck & Co., Inc.
• 15. Mitsubishi Tanabe Pharma Corporation
• 16. Novartis International AG
• 17. Novavax, Inc.
• 18. Pfizer, Inc.
• 19. Sanofi SA
• 20. Serum Institute of India Pvt., Ltd
• 21. Sinovac Biotech Ltd.